Adhesive articles

1. An adhesive article comprising:

a biocompatible and at least partially biodegradable substrate having a surface and protrusions extending from the surface;

wherein the protrusions comprise a biocompatible and at least partially biodegradable material,

wherein the protrusions have an average height of less than approximately 1,000 μm, and

wherein the protrusions have a tip width to pitch ratio (T/P) ranging from about 0.8 to about 0.1.

2. The adhesive article of claim 1 , wherein the tip width to pitch ratio (T/P) is from about 0.6 to about 0.2.

3. The adhesive article of claim 1 , wherein the protrusions have an average tip width of from approximately 0.05 μm to approximately 10 μm.

4. The adhesive article of claim 1 , wherein the protrusions have an average base width of from approximately 0.05 μm to approximately 10 μm.

5. The adhesive article of claim 1 , wherein the protrusions have a base width to tip width ratio (B/T) in the range of from about 2:1 to about 20:1.

6. The adhesive article of claim 1 , wherein the protrusions have an average height of from approximately 0.25 μm to approximately 10 μm.

7. The adhesive article of claim 1 , wherein the protrusions have an average center-to-center pitch from approximately 0.2 μm to approximately 100 μm.

8. The biocompatible adhesive article of claim 1 , wherein the substrate comprises poly(glycerol sebacate) (PGS), poly(glycerol sebacate acrylate) (PGSA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polyglycolide (PGA), polylactic acid (PLA), poly-3-hydroxybutyrate (PHB), star-poly-caprolactone-co-D,L-lactide, poly(tri-methyl carbonate-co-caprolactone), poly(ethylene glycol) (PEG), polyurethane, parylene-C, poly(citric-diol), hyaluronic acid, dextran, chitosan, alginate, keratin, carbon nanotubes, or agrose.

9. The adhesive article of claim 1 , wherein the biocompatible adhesive article further comprises a biomolecule or a pharmaceutical compound.

10. The adhesive article of claim 9 , wherein the biomolecule or pharmaceutical compound is selected from the group consisting of anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants, anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or antiprotozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and pro- or anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, pro- or anti-angiogenic factors, pro- or anti-secretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics, prostaglandins, antidepressants, anti-psychotic substances, anti-emetics, growth factors, proton pump inhibitors, hormones, vitamins, gene delivery systems, and imaging agents.

11. The adhesive article of claim 1 , further comprising a plurality of cells.

12. The adhesive article of claim 11 , wherein the plurality of cells comprises one or more kerotinocytes, fibroblasts, ligament cells, endothelial cells, lung cells, epithelial cells, smooth muscle cells, cardiac muscle cells, skeletal muscle cells, islet cells, nerve cells, hepatocytes, kidney cells, bladder cells, urothelial cells, stem cells, neurobalstoma, chondrocytes, skin cells and bone-forming cells.

13. The adhesive article of claim 1 , further comprising an adherent layer having a moiety capable of bonding to the biological tissue.

14. The adhesive article of claim 13 , wherein the moiety capable of bonding to the biological tissue comprises aldehydes.